These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28638342)

  • 1. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.
    Claudio-Campos K; Labastida A; Ramos A; Gaedigk A; Renta-Torres J; Padilla D; Rivera-Miranda G; Scott SA; Ruaño G; Cadilla CL; Duconge-Soler J
    Front Pharmacol; 2017; 8():347. PubMed ID: 28638342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
    Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
    Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
    Villagra D; Duconge J; Windemuth A; Cadilla CL; Kocherla M; Gorowski K; Bogaard K; Renta JY; Cruz IA; Mirabal S; Seip RL; Ruaño G
    Clin Chim Acta; 2010 Sep; 411(17-18):1306-11. PubMed ID: 20488169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
    Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
    Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
    Claudio-Campos KI; González-Santiago P; Renta JY; Rodríguez J; Carrasquillo K; Gaedigk A; Roche A; Ducongé J
    Pharmacogenomics; 2019 Jan; 20(1):3-8. PubMed ID: 30518301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-frequency variants at the
    Claudio-Campos K; Moneró-Paredes M; Hernández E; Renta J; Duconge J
    Pharmacogenomics; 2019 Aug; 20(12):891-902. PubMed ID: 31453773
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.
    Valentín II; Rivera G; Nieves-Plaza M; Cruz I; Renta JY; Cadilla CL; Feliu JF; Seip RL; Ruaño G; Duconge J
    P R Health Sci J; 2014 Sep; 33(3):97-104. PubMed ID: 25244877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Al-Eitan LN; Almasri AY; Khasawneh RH
    Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30486437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
    Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
    Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.